SG10201913432RA - Antigen-binding proteins that activate the leptin receptor - Google Patents
Antigen-binding proteins that activate the leptin receptorInfo
- Publication number
- SG10201913432RA SG10201913432RA SG10201913432RA SG10201913432RA SG10201913432RA SG 10201913432R A SG10201913432R A SG 10201913432RA SG 10201913432R A SG10201913432R A SG 10201913432RA SG 10201913432R A SG10201913432R A SG 10201913432RA SG 10201913432R A SG10201913432R A SG 10201913432RA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen
- activate
- binding proteins
- leptin receptor
- leptin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240021P | 2015-10-12 | 2015-10-12 | |
| US201662359757P | 2016-07-08 | 2016-07-08 | |
| US201662375495P | 2016-08-16 | 2016-08-16 | |
| US201662393143P | 2016-09-12 | 2016-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913432RA true SG10201913432RA (en) | 2020-03-30 |
Family
ID=57184864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913432RA SG10201913432RA (en) | 2015-10-12 | 2016-10-11 | Antigen-binding proteins that activate the leptin receptor |
Country Status (32)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752920B (zh) * | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| FI3538554T3 (fi) * | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
| KR102715225B1 (ko) | 2017-05-05 | 2024-10-14 | 리제너론 파아마슈티컬스, 인크. | 자동 주사기 |
| AU2018390811A1 (en) * | 2017-12-18 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof |
| CA3094400A1 (en) * | 2018-04-06 | 2019-10-10 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
| WO2020075417A1 (ja) * | 2018-10-11 | 2020-04-16 | 住友化学株式会社 | プロピレンオキサイド精製装置、及び、プロピレンオキサイドの製造方法 |
| WO2020160199A1 (en) | 2019-01-31 | 2020-08-06 | Siemens Healthcare Diagnostics Inc. | Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| GB2600273B (en) * | 2019-07-02 | 2024-06-05 | Univ Shanghai Technology | Antibody to leptin receptor |
| US11392515B2 (en) | 2019-12-03 | 2022-07-19 | Micron Technology, Inc. | Cache architecture for a storage device |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| PE20231657A1 (es) * | 2020-09-15 | 2023-10-17 | Regeneron Pharma | Uso de agonistas de lepr para el dolor |
| WO2022178382A1 (en) | 2021-02-22 | 2022-08-25 | Regeneron Pharmaceuticals, Inc. | Method for diagnosing and treating partial lipodystrophy |
| CN114456124B (zh) * | 2021-12-30 | 2023-04-21 | 华南农业大学 | 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用 |
| TW202515628A (zh) | 2023-06-16 | 2025-04-16 | 美商再生元醫藥公司 | 醫療裝置包裝及相關方法 |
| US20250108173A1 (en) | 2023-10-02 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Drug delivery device safety system |
| JP2025148269A (ja) | 2024-03-15 | 2025-10-07 | イーライ リリー アンド カンパニー | 肥満を治療するための単独又は併用療法としてのレプチン受容体アゴニスト抗体 |
| WO2025227054A1 (en) * | 2024-04-25 | 2025-10-30 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies binding to leptin and uses thereof |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| US6977240B1 (en) * | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| ATE307887T1 (de) | 1996-01-08 | 2005-11-15 | Genentech Inc | Ob-rezeptor und liganden |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| EP1731164A1 (en) | 1996-01-23 | 2006-12-13 | Indevus Pharmaceuticals, Inc. | Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| AUPN780096A0 (en) * | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| PL214862B1 (pl) | 2001-10-22 | 2013-09-30 | Amgen | Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny |
| WO2003049673A2 (en) * | 2001-12-05 | 2003-06-19 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| WO2005056602A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | アゴニスト活性を有する改変抗体のスクリーニング方法 |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| US7575878B2 (en) | 2004-11-18 | 2009-08-18 | Vib Vzw | Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| US20100260772A1 (en) | 2007-09-28 | 2010-10-14 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing diseases associated with low bone mass |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| ES2948572T3 (es) | 2009-07-08 | 2023-09-14 | Kymab Ltd | Modelos de roedores y moléculas terapéuticas |
| ES2547142T5 (es) | 2010-02-08 | 2021-12-09 | Regeneron Pharma | Cadena ligera común de ratón |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| RU2620071C2 (ru) | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| EP2672999A2 (en) | 2011-02-10 | 2013-12-18 | Roche Glycart AG | Improved immunotherapy |
| HUE024534T2 (hu) | 2011-02-25 | 2016-01-28 | Regeneron Pharma | ADAM6 egerek |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| IL273982B2 (en) | 2011-08-05 | 2023-03-01 | Regeneron Pharma | Humanized mice possess a universal light chain |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| RU2014153674A (ru) | 2012-06-05 | 2016-07-27 | Регенерон Фармасьютикалз, Инк. | Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи |
| PL2895513T3 (pl) | 2012-09-12 | 2018-11-30 | Genzyme Corporation | FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| ES2831014T3 (es) | 2014-02-18 | 2021-06-07 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la vía de señalización del complejo NRP-1/OBR |
| TWI752920B (zh) * | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| FI3538554T3 (fi) | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
| CN107760761A (zh) | 2017-11-10 | 2018-03-06 | 江苏省农业科学院 | 一种加强瘦素激发lepr信号转导的方法 |
| AU2018390811A1 (en) | 2017-12-18 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof |
| CA3094400A1 (en) | 2018-04-06 | 2019-10-10 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
-
2016
- 2016-10-07 TW TW105132493A patent/TWI752920B/zh active
- 2016-10-07 TW TW111100429A patent/TWI824372B/zh active
- 2016-10-07 TW TW112125041A patent/TW202417497A/zh unknown
- 2016-10-11 HU HUE16785072A patent/HUE058280T2/hu unknown
- 2016-10-11 AU AU2016338851A patent/AU2016338851B2/en active Active
- 2016-10-11 BR BR112018007318-0A patent/BR112018007318A2/en active Search and Examination
- 2016-10-11 PT PT167850726T patent/PT3362477T/pt unknown
- 2016-10-11 EA EA201890928A patent/EA201890928A1/ru unknown
- 2016-10-11 EP EP21207469.4A patent/EP4071173A1/en active Pending
- 2016-10-11 SI SI201631477T patent/SI3362477T1/sl unknown
- 2016-10-11 PL PL16785072T patent/PL3362477T3/pl unknown
- 2016-10-11 CA CA3000215A patent/CA3000215A1/en active Pending
- 2016-10-11 UA UAA201803447A patent/UA124419C2/uk unknown
- 2016-10-11 KR KR1020187013185A patent/KR20180070609A/ko not_active Ceased
- 2016-10-11 MY MYPI2018701183A patent/MY187975A/en unknown
- 2016-10-11 LT LTEPPCT/US2016/056465T patent/LT3362477T/lt unknown
- 2016-10-11 HR HRP20220426TT patent/HRP20220426T8/hr unknown
- 2016-10-11 JP JP2018518592A patent/JP7034068B2/ja active Active
- 2016-10-11 RS RS20220294A patent/RS63061B1/sr unknown
- 2016-10-11 EP EP16785072.6A patent/EP3362477B1/en active Active
- 2016-10-11 UY UY0001036942A patent/UY36942A/es not_active Application Discontinuation
- 2016-10-11 IL IL300961A patent/IL300961B2/en unknown
- 2016-10-11 DK DK16785072.6T patent/DK3362477T3/da active
- 2016-10-11 SG SG10201913432RA patent/SG10201913432RA/en unknown
- 2016-10-11 KR KR1020257014408A patent/KR20250069979A/ko active Pending
- 2016-10-11 MX MX2018004531A patent/MX2018004531A/es unknown
- 2016-10-11 ES ES16785072T patent/ES2908574T3/es active Active
- 2016-10-11 US US15/290,967 patent/US10023644B2/en active Active
- 2016-10-11 IL IL316563A patent/IL316563A/en unknown
- 2016-10-11 CN CN201680072173.1A patent/CN108368177B/zh active Active
- 2016-10-11 SM SM20220125T patent/SMT202200125T1/it unknown
- 2016-10-11 WO PCT/US2016/056465 patent/WO2017066204A1/en not_active Ceased
-
2018
- 2018-03-26 PH PH12018500663A patent/PH12018500663A1/en unknown
- 2018-03-26 ZA ZA2018/01975A patent/ZA201801975B/en unknown
- 2018-03-29 IL IL258448A patent/IL258448B2/en unknown
- 2018-04-11 CO CONC2018/0003852A patent/CO2018003852A2/es unknown
- 2018-04-12 CL CL2018000946A patent/CL2018000946A1/es unknown
- 2018-04-12 MX MX2023000738A patent/MX2023000738A/es unknown
- 2018-06-13 US US16/007,812 patent/US10618968B2/en active Active
- 2018-06-13 US US16/007,848 patent/US10253102B2/en active Active
-
2019
- 2019-05-28 CL CL2019001434A patent/CL2019001434A1/es unknown
- 2019-10-04 US US16/593,761 patent/US20200031946A1/en not_active Abandoned
-
2021
- 2021-03-11 JP JP2021039405A patent/JP7165225B2/ja active Active
- 2021-11-30 US US17/539,034 patent/US12275792B2/en active Active
-
2022
- 2022-03-31 CY CY20221100249T patent/CY1125102T1/el unknown
- 2022-10-21 JP JP2022169008A patent/JP7436603B2/ja active Active
-
2023
- 2023-07-19 AU AU2023206125A patent/AU2023206125A1/en active Pending
- 2023-11-30 JP JP2023202680A patent/JP7699191B2/ja active Active
-
2024
- 2024-02-09 JP JP2024018406A patent/JP7759417B2/ja active Active
- 2024-08-20 US US18/810,454 patent/US20250051465A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201913432RA (en) | Antigen-binding proteins that activate the leptin receptor | |
| ZA201900373B (en) | Anti-tim-3 antibodies | |
| IL257233B (en) | Monoclonal antibodies against bcma | |
| SG10201601719RA (en) | Anti-LAG-3 Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| IL253633A0 (en) | Anti-transthyretin antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| GB201521391D0 (en) | Antibodies | |
| GB201521382D0 (en) | Antibodies | |
| GB201610044D0 (en) | Antibodies | |
| GB201508180D0 (en) | Antibodies | |
| ZA201808317B (en) | Anti-tnfrsf25 antibodies | |
| GB201616699D0 (en) | Antibodies | |
| SG10201913470SA (en) | Antigen-binding proteins that antagonize leptin receptor | |
| GB201603291D0 (en) | Antibodies | |
| PT3484921T (pt) | Anticorpos anti-il-22r | |
| GB201509907D0 (en) | Antibodies | |
| GB201522394D0 (en) | Antibodies | |
| GB201622197D0 (en) | Antibodies | |
| GB201620414D0 (en) | Antibodies | |
| GB201615224D0 (en) | Antibodies | |
| GB201613158D0 (en) | Antibodies | |
| GB201612437D0 (en) | Anti-lag-3 antibodies | |
| GB201518728D0 (en) | Antibodies | |
| GB201515570D0 (en) | Anti-LAG-3 antibodies |